MapLight Therapeutics, Inc. Operating Income
MapLight Therapeutics, Inc. (MPLT) reported Operating Income of -$63.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- MapLight Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$63.55M.
- MapLight Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$64.50M.
- MapLight Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$83.38M.
- MapLight Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$31.50M.
- MapLight Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$169.08M.
- MapLight Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$82.95M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$63.55M 10-Q · filed 2026-08-13 | -$128.05M 10-Q · filed 2026-08-13 | -$211.43M derived: sum of 3 quarters · filed 2026-08-13 | -$242.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$64.50M 10-Q · filed 2026-05-14 | -$147.88M derived: sum of 2 quarters · filed 2026-05-14 | -$179.38M derived: sum of 3 quarters · filed 2026-05-14 | -$210.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$83.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$114.88M derived: sum of 2 quarters · filed 2026-03-26 | -$145.54M derived: sum of 3 quarters · filed 2026-08-13 | -$169.08M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$31.50M 10-Q · filed 2025-12-04 | -$62.16M derived: sum of 2 quarters · filed 2026-08-13 | -$85.71M 10-Q · filed 2025-12-04 | -$108.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$30.66M 10-Q · filed 2026-08-13 | -$54.21M 10-Q · filed 2026-08-13 | -$76.98M derived: sum of 3 quarters · filed 2026-08-13 | -$97.88M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$23.54M 10-Q · filed 2026-05-14 | -$46.32M derived: sum of 2 quarters · filed 2026-05-14 | -$67.21M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$22.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$43.67M derived: sum of 2 quarters · filed 2026-03-26 | -$82.95M 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$20.89M 10-Q · filed 2025-12-04 | -$60.17M 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |